APM
NMRA icon

Avidity Partners Management’s Neumora Therapeutics NMRA Stock Holding History

Avidity Partners Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$1.59M – 80
2024
Q4 		$1.59M Buy
+150,000
New +$1.8M 0.16% 59

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Avidity Partners Management's NMRA Position: Q4 2024 in Review

Avidity Partners Management sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 1,800,000 shares — an estimated $21.6M sold.

Avidity Partners Management first reported a position in NMRA in Q3 2023 and held it in 5 quarters. The position peaked at $33.9M in Q4 2023. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Avidity Partners Management reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 1,800,000 Neumora Therapeutics shares in Q4 2024, an estimated $21.6M.
  • Avidity Partners Management first reported a position in Neumora Therapeutics in Q3 2023 and held it in 5 quarters.
  • Avidity Partners Management's Neumora Therapeutics position peaked at $33.9M in Q4 2023.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.